ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0699

Lumbar Spine Stenosis Treatment : Is Surgery Better Than Medical Treatment in Afro-Descendant Populations ?
Abstract Number: 0700

Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
Abstract Number: 0701

miRNome Sequencing Identifies a Unique Profile of Circulating MicroRNAs in Early Knee Osteoarthritis
Abstract Number: 0702

Distinct Murine Cartilage Microbial DNA Signatures Are Seen in High Fat Diet-Induced Obesity and Aging
Abstract Number: 0703

Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect
Abstract Number: 0704

The Murine Ear Wound Cartilage Superhealer Trait, Mediated by the Gut Microbiome, Is Transgenerationally Heritable Following Cecal Transplantation
Abstract Number: 0705

lncRNA H19 and Micro RNA 675-3p Are Altered by Visfatin During Osteogenesis
Abstract Number: 0706

Adenosine A2A Receptor Activation Reduces Markers of Chondrocyte Senescence and Cartilage Inflammation Associated with Osteoarthritis
Abstract Number: 0707

Contribution of NOTUM and Glypicans to the Development of Osteoarthritis
Abstract Number: 0708

Differences in Treating Knee Osteoarthritis by Clinician Specialty
Abstract Number: 0709

Anatomical Distribution of Mrgprd-expressing Nonpeptidergic C-fibers in the Mouse Knee
Abstract Number: 0710

Early Start of Biological Treatment in Juvenile Idiopathic Arthritis: Does a Therapeutic Window Exist in Real Life?
Abstract Number: 0711

Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 0712

Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Abstract Number: 0713

Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].